Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : FDA Gives Orphan Drug Status to Two Liver Cancer Drugs

share with twitter share with LinkedIn share with facebook
share via e-mail
01/20/2020 | 02:34am EST

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) said Monday that two of its medicines were granted orphan drug status by the U.S. Food and Drug Administration for the treatment of a common type of liver cancer.

The designation is awarded to drugs that are intended to treat rare disease and provides benefits such as market exclusivity and faster regulatory approvals.

Imfinzi and tremelimumab were given orphan drug status as treatments for hepatocellular carcinoma, or HCC. Imfinzi is already approved for other types of cancer, while tremelimumab is currently being investigated as a potential treatment.

The two drugs are being jointly studied in the phase 3 Himalaya clinical trial as treatments for a type of inoperable and advanced HCC.

Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
02/20EXCLUSIVE : Canadian regulator considers changes to new drug pricing plan
RE
02/18Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan
RE
02/17ASTRAZENECA PLC : - Full-year and Q4 2019 results
AQ
02/14Health Care Flat Amid Mixed Earnings Season -- Health Care Roundup
DJ
02/14EUROPE : European shares settle below record highs
RE
02/14FTSE 100 ends week lower after week AstraZeneca, RBS results
RE
02/14NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/14GLOBAL MARKETS LIVE: Facebook ready to pay more taxes, Amazon gets JEDI suspe..
02/14AstraZeneca's CEO reaffirms 2021 targets
RE
02/14AstraZeneca braces for coronavirus hit, but no impact so far
RE
More news
Financials (USD)
Sales 2020 27 106 M
EBIT 2020 7 449 M
Net income 2020 3 013 M
Debt 2020 13 206 M
Yield 2020 2,86%
P/E ratio 2020 40,4x
P/E ratio 2021 27,4x
EV / Sales2020 5,31x
EV / Sales2021 4,77x
Capitalization 131 B
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 107,31  $
Last Close Price 99,69  $
Spread / Highest target 38,9%
Spread / Average Target 7,64%
Spread / Lowest Target -25,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC1.09%130 836
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679